TP53 and cancer: For example, research has shown that restoring normal apoptotic responses through CRISPR-Cas9-mediated restoration of wild-type TP53 in cancer cells can desensitise them to chemotherapy and radiation therapy (Wiegering et al., 2017; Tang et al., 2019).